Medarex

Medarex is a biopharmaceutical company focused on the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. Medarex was acquired by Bristol-Myers Squibb for $2.4 billion in July 2009.